Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence

AIDS. 2006 Nov 14;20(17):2199-206. doi: 10.1097/QAD.0b013e3280106d6a.

Abstract

Objectives: To measure the burden of disease and describe the epidemiology of cryptococcosis in Gauteng Province, South Africa.

Design and methods: The study was an active, prospective, laboratory-based, population-based surveillance. An incident case of cryptococcosis was defined as the first isolation by culture of any Cryptococcus species from any clinical specimen, a positive India ink cryptococcal latex agglutination test or a positive histopathology specimen from a Gauteng resident. Cases were identified prospectively at all laboratories in Gauteng. Case report forms were completed using medical record review and patient interview where possible.

Results: Between 1 March 2002 and 29 February 2004, 2753 incident cases were identified. The overall incidence rate was 15.6/100 000. Among HIV-infected persons, the rate was 95/100 000, and among persons living with AIDS 14/1000. Males and children under 15 years accounted for 49 and 0.9% of cases, respectively. The median age was 34 years (range, 1 month-74 years). Almost all cases (97%) presented with meningitis. Antifungal therapy was given to 2460 (89%) cases of which 72% received fluconazole only. In-hospital mortality was 27% (749 cases). Recurrences occurred in 263 (9.5%) incident cases. Factors associated with death included altered mental status, coma or wasting; factors associated with survival included employment in the mining industry, visual changes or headache on presentation.

Conclusions: This study demonstrates the high disease burden due to cryptococcosis in an antiretroviral-naive South African population and emphasizes the need to improve early recognition, diagnosis and treatment of the condition.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / mortality*
  • Adolescent
  • Adult
  • Aged
  • Antifungal Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cost of Illness
  • Cryptococcosis / drug therapy
  • Cryptococcosis / mortality*
  • HIV Seroprevalence*
  • Humans
  • Incidence
  • Infant
  • Meningitis, Cryptococcal / drug therapy
  • Meningitis, Cryptococcal / mortality
  • Middle Aged
  • Population Surveillance
  • Recurrence
  • South Africa / epidemiology
  • Treatment Outcome

Substances

  • Antifungal Agents